Instructions for use of Laos Lucius version of cabozantinib generic drug

The Laos Lucius version of cabozantinib, a high-profile generic multi-target tyrosine kinase inhibitor, has brought new hope to many patients suffering from cancer. Its specification of 20mg*90 tablets/box and its affordable price of more than 800 RMB make this effective treatment affordable for more patients.

Cabozantinib has shown good therapeutic effects on a variety of cancers in clinical trials. Cabozantinib has shown significant efficacy in patients with advanced renal cancer, hepatocellular carcinoma (HCC) who have been treated with sorafenib, and as a first-line treatment in combination with nivolumab for advanced renal cell carcinoma. In addition, it also provides a new treatment strategy for patients with locally advanced or metastatic differentiated thyroid cancer (DTC), especially those whose disease has progressed after previous VEGFR-targeted therapy and are not suitable for radioactive iodine therapy.

When using the Laos Lucius version of cabozantinib generics, patients need to follow the corresponding medication regimen according to different types of cancer. For patients with renal cell carcinoma, it is recommended to take a dose of 60mg once daily on an empty stomach to ensure optimal absorption of the drug. Patients should take care to swallow the tablets whole and avoid crushing. If you accidentally miss a dose, you should not take it within 12 hours before the next dose to avoid affecting the efficacy of the medicine.

For patients with liver cancer, it is also recommended to take 60 mg of cabozantinib on an empty stomach every day until the disease progresses or the toxicity reaches intolerable levels. Precautions during medication are the same as those for patients with renal cell carcinoma.

When cabozantinib is used in combination with nivolumab, it is recommended to adjust the dose to 40 mg daily and continue treatment until disease progression or unacceptable toxicity. The principle of taking on an empty stomach still applies in this regimen.

For patients with differentiated thyroid cancer, the recommended dose is adjusted based on the patient's body surface area (BSA). Patients 12 years and older with a BSA greater than or equal to 1.2m2 are recommended to take 60mg daily; while similar patients with a BSA less than 1.2m2 are recommended to reduce the dose to 40mg daily. Patients need to continue taking the drug until disease progression or toxicity becomes intolerable.

All in all, during the use of the Laos Lucious version of cabozantinib generics, patients should pay close attention to their physical condition and regularly report their medication and any uncomfortable reactions to their doctors. By strictly following medical instructions, using medications rationally, and maintaining close communication with doctors, patients can better manage their health conditions, thereby improving their quality of life and extending their survival.